Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA-MI.
Saved in:
| Title: | Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA-MI. |
|---|---|
| Authors: | Erlinge D; Department of Cardiology, Clinical Sciences, Lund University, Lund, Sweden., James S; Uppsala Clinical Research Center, Uppsala, Sweden.; Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden., Deanfield J; Institute of Cardiovascular Sciences, University College London, London, UK., Eriksson N; Uppsala Clinical Research Center, Uppsala, Sweden., de Belder M; National Institute for Cardiovascular Outcomes Research (NICOR), NHS Arden and Greater East Midlands Commissioning Support Unit, Leicester, UK., Alchay M; North Älvsborg County Hospital, Trollhättan, Sweden., Austin D; Academic Cardiovascular Unit, The James Cook University Hospital, South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK.; Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK., Jones DA; William Harvey Research Institute, Barts and The London Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.; Department of Cardiology, St Bartholomew's Hospital, West Smithfield, London, UK., Ravn-Fischer A; Institute of Medicine, Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.; Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden., Sederholm Lawesson S; Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.; Department of Cardiology, Linköping University Hospital, Linköping, Sweden., Shah N; Queen Alexandra Hospital, Portsmouth, UK., Strange JW; Department of Cardiology, Bristol Heart Institute, University Hospital Bristol NHS Foundation Trust, Bristol, UK.; Weston Area Health NHS Trust, Bristol, UK., Szummer K; Department of Cardiology, Karolinska University Hospital, Huddinge, Stockholm, Sweden.; Department of Medicine, Karolinska Institutet, Stockholm, Sweden., Ridderstråle W; Late-Stage Development, Cardiovascular, Renal and Metabolism, Bio-Pharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden., Parvaresh Rizi E; Late-Stage Development, Cardiovascular, Renal and Metabolism, Bio-Pharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden., Langkilde AM; Late-Stage Development, Cardiovascular, Renal and Metabolism, Bio-Pharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden., Johansson PA; Late-Stage Development, Cardiovascular, Renal and Metabolism, Bio-Pharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden., McGuire DK; Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.; Division of Cardiology, Parkland Health System, Dallas, Texas, USA., Oldgren J; Uppsala Clinical Research Center, Uppsala, Sweden.; Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden., Storey RF; Division of Clinical Medicine, University of Sheffield, Sheffield, UK.; NIHR Sheffield Biomedical Research Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. |
| Source: | ESC heart failure [ESC Heart Fail] 2025 Dec; Vol. 12 (6), pp. 4184-4193. Date of Electronic Publication: 2025 Sep 16. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Multicenter Study |
| Journal Info: | Publisher: John Wiley & Sons Ltd on behalf of the European Society of Cardiology Country of Publication: England NLM ID: 101669191 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2055-5822 (Electronic) Linking ISSN: 20555822 NLM ISO Abbreviation: ESC Heart Fail Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2055-5822 |
|---|---|
| DOI: | 10.1002/ehf2.15420 |
